Cutting-Edge Cancer Treatment RefleXion Medical offers SCINTIX biology-guided radiotherapy, a revolutionary cancer treatment that detects cancer signals and delivers immediate targeted therapy. This unique approach can be positioned as a cutting-edge solution for cancer care institutions seeking innovative treatment options for their patients.
Recent Strategic Partnerships RefleXion Medical has established partnerships with companies like 3B Pharmaceuticals GmbH, expanding its reach and offerings in the oncology sector. Sales professionals can leverage these partnerships to showcase a broad network and comprehensive solutions to potential clients looking for holistic cancer treatment solutions.
Innovative Product Launches With the launch of RefleXion X1 at ASTRO 2023 Annual Meeting, RefleXion Medical introduced a game-changing technology in the form of SCINTIX biology-guided radiotherapy. Sales teams can capitalize on this recent product launch to engage with healthcare facilities looking to adopt state-of-the-art radiation therapy systems.
Funding and Financial Stability Having secured $105 million in funding and reporting revenue in the range of $50-100 million, RefleXion Medical demonstrates financial stability and growth potential. This information can be utilized by sales professionals to build trust with clients, assuring them of the company's sustainability and ability to support their long-term needs.
Competitive Positioning in the Market Compared to similar companies like Accuray and Elekta, RefleXion Medical stands out with its unique technology and recent advancements. Sales development representatives can highlight this competitive positioning to showcase RefleXion as a forward-thinking and differentiated player in the medical equipment manufacturing industry, potentially attracting clients seeking innovative radiation therapy solutions.
RefleXion Medical uses 8 technology products and services including SOLIDWORKS, NoSQL, ADP HRMS, and more. Explore RefleXion Medical's tech stack below.
| RefleXion Medical Email Formats | Percentage |
| FLast@reflexionmedical.com | 80% |
| First@reflexionmedical.com | 9% |
| First.Last@reflexionmedical.com | 5% |
| FirstLast@reflexionmedical.com | 3% |
| Last@reflexionmedical.com | 2% |
| FMiddleLast@reflexionmedical.com | 1% |
| FLast@reflexion.com | 74% |
| Last@reflexion.com | 15% |
| First@reflexion.com | 8% |
| First.Last@reflexion.com | 3% |
Medical Equipment ManufacturingCalifornia, United States201-500 Employees
SCINTIX biology-guided radiotherapy now FDA cleared. SCINTIX® therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
Company Overview
Funding & FinancialsRefleXion Medical has raised a total of $105M of funding over 11 rounds. Their latest funding round was raised on Nov 15, 2023 in the amount of $105M.
RefleXion Medical's revenue is in the range of $50M$100M
Funding & FinancialsRefleXion Medical has raised a total of $105M of funding over 11 rounds. Their latest funding round was raised on Nov 15, 2023 in the amount of $105M.
RefleXion Medical's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com